Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

University Hospital, Brest20 enrolled

Overview

Abatacept disrupts T-cell coactivation signals in rheumatoid arthritis (RA). Its potential effects on B cells are not well described. This study will assess the effects of abatacept therapy on the phenotype and function of peripheral blood B cells in patients with RA.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * RA as defined by ACR/EULAR criteria * Clinical indication to start abatacept therapy Exclusion Criteria: * Treatment by rituximab in the previous year

Locations (1)

CHRU de Brest

Brest, France

Outcomes

Primary Outcomes

Peripheral blood B-cell phenotype changes

Measure of the proportion of the main B-cell subsets (transitional, naïve, memory, plasmablasts) by FACS analysis before abatacept initiation and 3 months later.

Time frame: 3 months

Secondary Outcomes

In vitro B-cell function and regulatory properties

In vitro culture of B cells from the patients to assess B cell inhibition of T cell proliferation before abatacept initiation and 3 months later.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.